QXO Launches $11B Hostile Tender Offer for Beacon Roofing Supply

Building-products distributor QXO has launched a hostile tender offer directly to Beacon Roofing Supply shareholders after the target company repeatedly rejected its takeover bids, valuing the firm at approximately $11 billion including debt.

Under the terms of the hostile move, QXO is offering $124.25 per share in cash while concurrently nominating an alternative slate of independent directors to replace Beacon's current board. The aggressive escalation comes as consolidation sweeps the building-materials sector, pitting billionaire dealmaker Brad Jacobs against an established roofing distributor defending its independence.

"We are proposing a slate of high-caliber, independent director nominees who are astute at delivering value to shareholders of large public companies. If elected, our nominees would give Beacon’s shareholders a direct voice in advocating for an independent evaluation of QXO’s proposal," said Brad Jacobs, chairman and chief executive officer of QXO.

Beacon's board swiftly moved to fend off the unsolicited approach by adopting a shareholder rights plan, commonly known as a poison pill, and began soliciting interest from alternative buyers to explore potential rival bids. Company executives argued that the cash offer undervalues the distributor's long-term business prospects.

In regulatory filings, Beacon labeled the approach "an opportunistic attempt to take advantage of the current macro environment and acquire Beacon at a discount to its intrinsic value." Despite the board's resistance, QXO's proposal has already cleared regulatory hurdles, receiving preclearance from antitrust competition watchdogs in both the United States and Canada.

Mechanics of the Hostile Bid

A hostile tender offer bypasses target management entirely, allowing an acquirer to purchase shares directly from existing investors if enough stockholders tender their holdings. By taking the $124.25-per-share offer straight to the market alongside a proxy contest for board seats, QXO aims to strip away the defenses erected by Beacon's leadership.

Poison pills typically dilute an acquirer's stake or make unauthorized acquisitions prohibitively expensive by allowing other shareholders to buy discounted shares upon crossing a specific ownership threshold. To succeed, QXO will need to convince institutional investors that its premium price outweighs Beacon's standalone growth strategy, making the upcoming shareholder vote a critical battleground for control of the distributor.